360 Stem Cell & Regenerative Medicine Newsletter- June 16, 2015

 weSRCH's Best of the Internet Award
  16th-Jun-2015
 283

360 Stem Cell & Regenerative Medicine Newsletter - June 16, 2015

Featured Video from Morgridge Institute for Research: Blue Sky Science: How can we use stem cells to build tissues and organs?

Blue Sky Science is a collaboration of the Wisconsin State Journal and the Morgridge Institute for Research. The questions are posed by visitors to Science Saturdays at the Discovery Building, a monthly series that features interactive exploration stations centered around a particular topic.

World Stem Cell Summit

Scripps Florida Scientists Identify a Potential New Treatment for Osteoporosis
“Scientists from the Florida campus of The Scripps Research Institute (TSRI) have identified a new therapeutic approach that, while still preliminary, could promote the development of new bone-forming cells in patients suffering from bone loss. The study, published in the journal Nature Communications, focused on a protein called PPARy (known as the master regulator of fat) and its impact on the fate of stem cells derived from bone marrow (“mesenchymal stem cells”). MSC’s can develop into several different cell types—including fat, connective tissues, bone and cartilage—they have a number of potentially important therapeutic applications.”

RMF/GPI: World Stem Cell Summit & RegMed Capital Conference Weekly Update
Registration opened for the 11th World Stem Cell Summit and the RegMed Capital Conference at the Hyatt Regency Atlanta (USA) December 10-13.

Newly confirmed speakers include:

Yuzo Toda is a Director of Japan’s FUJIFILM Holdings Corporation, Director, Senior Vice President, FUJIFILM Corporation and Chairman of Japan's industry alliance, the Forum for Innovative Regenerative Medicine (FIRM). Mr. Toda leads FUJIFILM”s robust growth in the area of regenerative medicine. Most recently the powerhouse company acquired the U.S.-based Cellular Dynamics Corporation and all of CDI’s iPS technologies. FIRM recently signed a MOU with Washington-based Alliance for Regenerative Medicine (ARM).

C. Randal Mills, PhD is thePresident & CEO, California Institute for Regenerative Medicine (CIRM). Under Dr. Mills’ dynamic leadership, the $3B California Stem Cell Agency launched CIRM 2.0 -accelerating grant approvals, translational activities and outreach.

Outi Hovatta, MD, PhD, is a professor of Obstetrics and Gynaecology at the Karolinska Institute in Sweden. Her research interest is mainly in infertility problems, the genetics behind it and the generation of optimized treatments for infertility. Outi is a pioneering scientist in the field of human embryonic stem cells, working specially with the generation of methods that may allow the cells to be use in clinical trials related with cell replacement therapies.

Wake Forest

NIH: A Patient’s Budding Cortex — in a Dish?
“An evolving “disease-in-a-dish” technology, funded by the National Institutes of Health (NIH), is bringing closer the day when such a seemingly futuristic personalized medicine scenario might not seem so far-fetched. Scientists have perfected mini cultured 3-D structures that grow and function much like the outer mantle – the key working tissue, or cortex — of the brain of the person from whom they were derived. Strikingly, these “organoids” buzz with neuronal network activity. Cells talk with each other in circuits, much as they do in our brains.
Sergiu Pasca, M.D., of Stanford University and colleagues, debut what they call “human cortical spheroids,” online in the journal Nature Methods.”

Icems

Researchers Develop New Technique for Modeling NIH: Neuronal Connectivity Using Stem Cells
In a new study published in Restorative Neurology and Neuroscience, researchers from the Intramural Research Program, National Institute on Drug Abuse at the National Institutes of Health in Baltimore reported successfully growing multiple brain structures and forming connections between them in vitro, in a single culture vessel, for the first time.

CCRM (Canada): New Company will Benefit Patients Undergoing Transplants for Leukemias
“Patients suffering from acute myeloid leukemia (AML), who require stem cell transplantation as part of their treatment, may now benefit from a new best-in-class process that improves the viability and success of cord blood stem cell transplantation. ExCellThera, a spin-off company launched by the Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR), and the Centre for Commercialization of Regenerative Medicine (CCRM) is based on novel proprietary intellectual property related to the expansion of stem cells.”

wiley

UGA Researchers Identify Unique Marker on Mom’s Chromosomes in Early Embryo- Study Able to Distinguish Chromosomes Inherited from Mom and Dad
‘Researchers in the University of Georgia's Regenerative Bioscience Center are visually capturing the first process of chromosome alignment and separation at the beginning of mouse development. The findings could lead to answers to questions concerning the mechanisms leading to birth defects and chromosome instability in cancer cells.”

Tech Times: Discovery of Vulnerability in Brain Tumor Stem Cells May Lead to Successful Brain Cancer Treatment
“Brain tumors may soon be treated by interrupting the process by which stem cells grow, a new study finds. Treatment usually consists of surgically removing the tumor, as well as some of the healthy material around it. However, this procedure can often result in the loss of brain functions, making surgery even more dangerous than usual.” The research from the Washington University School of Medicine in St. Louis was published in the journal Cell Reports.

Biobridge

BloombergBusiness: Nobel Laureate Shinya Yamanaka Allies with Takeda in Hunt for Blockbuster Drugs
Takeda Pharmaceutical and Nobel laureate Shinya Yamanaka, based in Kyoto University, agreed this year on a 10-year partnership to develop therapies for conditions such as heart failure and diabetes. The 20 billion yen ($160 million) accord, was the biggest between a university and a pharmaceutical company in Japan. This article in Bloomberg discussed some of the background about the transaction and the role of Takeda’s leader Christophe Weber.

PostBulletin.com: Former Cardio3 Launching $99M IPO in US and Worldwide- Based on Mayo Clinic Stem Cell Technology
Belgium-based Celyad, formerly Cardio3 Biosciences, has launched a $99 million stock offering. The company is building a manufacturing facility in downtown Rochester, Minnesota. This will likely benefit Mayo Clinic that owns an equity position in Cardio3. The company licensed stem-cell research by Mayo Clinic's Dr. Andre Terzic and Dr. Atta Behfar. The cardiopoiesis technology repairs patients' hearts by re-programming their own stem cells to regenerate cardiac tissue.

Wake Forest

CASIS Issues Request for Information On 3D Microphysiological Systems for Organs-On-Chips Research on the International Space Station
“The Center for the Advancement of Science in Space (CASIS) issued a Request for Information (RFI) that seeks to gather insight from subject matter experts and entities with experience in three-dimensional (3D) microphysiological systems for organs-on-chips research models. CASIS is tasked with managing and promoting research onboard the International Space Station U.S. National Laboratory, and this RFI is intended to precede a sponsored research program using these systems. The RFI is part of a CASIS initiative, Campaign Good Health, and represents an opportunity to bring new tools to biology, medicine, pharmacology, physiology, and toxicology for research applications on the ISS National Lab to benefit human disease research, tissue engineering, and regenerative medicine on Earth.”

Cosmos Magazine: The birth of IVF- A New Play Recounting the Saga of Alan Trounson
“The saga of Dr. Alan Trounson and the discovery of IVF has been made into a play “The Waiting Room” authored by Kylie Trounson- Alan’s daughter. An excerpt from the review: “Alan Trounson emerges as the hero of the piece – hardworking, optimistic, a loving father despite his long absences. Dr. Trounson divides his time between Australia and San Francisco where until mid-2014 he was president of the California Institute for Regenerative Medicine – a $3 billion stem cell agency. The social history of IVF may not sound like a promising subject for a play, but Kylie Trounson tackles the material imaginatively. Her words are ably brought to life by the ensemble cast.”

360 Newsletter Editor


Bernard Siegel
Executive Director
Genetics Policy Institute





Stem Cells and the Transformative Power of Hope-a TEDx talk by Bernard Siegel, Editor of 360 Newsletter

About GPI


The nonprofit Genetics Policy Institute (GPI) seeks to establish a positive policy, regulatory and societal framework to enable research to flourish, under the highest ethical and medical standards. We seek to accelerate the discovery and development of lifesaving cures and therapies to alleviate human suffering due to chronic and terminal afflictions. Visit Website.

ConnectGPI on FacebookGPI on TwitterGPI on LinkedIn


Genetics Policy Institute (GPI) and the Regenerative Medicine Foundation (RMF) Announce Merger Plan

Domain: Medical
Category: Biology
weSRCH App on Apple

Recent Newsletters

Linley Newsletter: August 8, 2019

Linley Newsletter Please feel free to forward this to your colleagues Issue #664 August 8, 2019 Independent Analysis of Microprocessors and the Semiconductor Industry E

08 August, 2019

Linley Newsletter: August 1, 2019

Linley Newsletter Please feel free to forward this to your colleagues Issue #663 August 1, 2019 Independent Analysis of Microprocessors and the Semiconductor Industry E

01 August, 2019

Linley Newsletter: July 25, 2019

Linley Newsletter Please feel free to forward this to your colleagues Issue #662 July 25, 2019 Independent Analysis of Microprocessors and the Semiconductor Industry

25 July, 2019